Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 6Fallopian Tube Neoplasms 5Uterine Cervical Neoplasms 4Endometrial Neoplasms 3Vulvar Neoplasms 2Vaginal Neoplasms 2Peritoneal Neoplasms 2Colorectal Neoplasms 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Recurrence 1Prostatic Neoplasms 1Platinum-resistant Recurrent Ovarian Cancer 1Neoplasm Metastasis 1Head and Neck Neoplasms 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Renal Cell 1Carcinoma, Pancreatic Ductal 1

Interventions

Bevacizumab 21-dodecylpyridoxal 2tremelimumab 1durvalumab 1Paclitaxel 1Injections 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Platinum-resistant Recurrent Ovarian Cancer × tremelimumab × Gynecologic × Clear all
NCT03699449 2021-04-01

An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION)

Yonsei University

Phase 2 Unknown
104 enrolled
Gynecologic

Platinum-resistant Recurrent Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡